Subscribe
shutterstock_2123228915_corona-borealis-studio
Shutterstock / Corona Borealis Studio
10 November 2022Big PharmaStaff Writer

SCOTUS rejects BMS vs Gilead patent clash

Dispute over patent relating to a CAR-T cell therapy shunned by top court | Backing from Amgen, GSK and St. Jude's Children's Research Hospital over “exceedingly narrow” patent protection fails to convince Justices.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
BMS petitions SCOTUS to revive $1.2bn win
16 June 2022   BMS unit Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have urged the US Supreme Court to reinstate their $1.2 billion win in a patent clash with Kite Pharma, a subsidiary of Gilead.
Americas
SCOTUS agrees to hear Amgen revival bid
7 November 2022   The dispute centres on a section of the Patent Act concerning 'enablement' | The US government had urged the court to deny the petition.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
BMS petitions SCOTUS to revive $1.2bn win
16 June 2022   BMS unit Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have urged the US Supreme Court to reinstate their $1.2 billion win in a patent clash with Kite Pharma, a subsidiary of Gilead.
Americas
SCOTUS agrees to hear Amgen revival bid
7 November 2022   The dispute centres on a section of the Patent Act concerning 'enablement' | The US government had urged the court to deny the petition.

More on this story

Big Pharma
BMS petitions SCOTUS to revive $1.2bn win
16 June 2022   BMS unit Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have urged the US Supreme Court to reinstate their $1.2 billion win in a patent clash with Kite Pharma, a subsidiary of Gilead.
Americas
SCOTUS agrees to hear Amgen revival bid
7 November 2022   The dispute centres on a section of the Patent Act concerning 'enablement' | The US government had urged the court to deny the petition.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?